skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Role of teriparatide in treatment of glucocorticoid-induced osteoporosis

Review

(1838) Views  (499) Full article downloads

Authors: Arthur N Lau, Jonathan D Adachi

Published Date October 2010 Volume 2010:6 Pages 497 - 503
DOI: http://dx.doi.org/10.2147/TCRM.S7776

Arthur N Lau, Jonathan D Adachi
Division of Rheumatology and Department of Medicine, St Joseph’s Healthcare and McMaster University, Hamilton, Ontario, Canada

Abstract: Glucocorticoids are commonly used in various fields within medicine. One of their most common and clinically significant side effects is glucocorticoid-induced osteoporosis (GIOP). GIOP is a disease leading to progressive decreases in bone mineral density, decreased bone strength, and increased risk of skeletal fractures. GIOP has a significant impact on the morbidity and health-related quality of life of the patients it affects. Glucocorticoids have deleterious effects on bone through promoting osteoblast apoptosis and inhibiting osteoblastogenesis. Teriparatide exerts anabolic effects on bone, so it is understandable why teriparatide is thought to be a rational treatment option. Clinical studies have indicated teriparatide is efficacious in the treatment of GIOP to improve bone mineral density values at the lumbar spine and femoral neck. Some evidence also suggests teriparatide may reduce rates of vertebral fractures in GIOP patients. Overall, this review of the current clinical evidence suggests teriparatide may be an efficacious and promising agent in the treatment of GIOP.

Keywords: glucocorticoid-induced osteoporosis, teriparatide, parathyroid hormone




 

Other articles by Dr Rick Adachi



Readers of this article also read:

Teriparatide in the management of osteoporosis
Management of glucocorticoids-induced osteoporosis: role of teriparatide
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Profile of teriparatide in the management of postmenopausal osteoporosis
Safety and tolerability of zoledronic acid and other bisphosphonates in osteoporosis management
Using systematically observed clinical encounters (SOCEs) to assess medical students’ skills in clinical settings
Effects of recombinant growth hormone replacement and physical rehabilitation in recovery of gross motor function in children with cerebral palsy
Experience with alendronate treatment for four years among Japanese men with osteoporosis or osteopenia and clinical risk factors for fractures
Efficacy and safety of bazedoxifene for postmenopausal osteoporosis
Osteopenia and osteoporosis in people living with HIV: multiprofessional approach